5 completed, 4 recruiting, 3 terminated, 2 unknown. 8 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Renal Cell Cancer Metastatic: new trials by email Literature Review of Renal Cell Cancer Metastatic trials Research Report on Renal Cell Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-03-25 | 2026-04-01 |
| Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma Renal Cell Cancer Metastatic | Recruiting | Zhe Chen | 145 | 2025-11-10 | 2025-12-05 | |
| Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma Renal Cell Cancer Metastatic | Completed | Spanish Oncology Genito-Urinary Group | 200 | 2025-05-13 | 2026-01-21 | |
| Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2 Biopsy - Kidney Cancer, Renal Cell Cancer Metastatic | Terminated | Ourotech, Inc. | 7 | 2024-06-19 | 2025-07-30 | |
| This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors ZM008 - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Zumutor Biologics Inc. | 100 | 2024-05-22 | 2026-04-02 |
| National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) Renal Cancer, Renal Cell Carcinoma | Recruiting | PROspective Renal Cancer Cohort Foundation | 2000 | 2023-01-19 | 2025-06-06 | |
| Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue meldonium - Renal Cell Cancer Metastatic, Kidney Cancer | Phase 1 / Phase 2 | Completed | Kidney Cancer Research Bureau | 60 | 2022-02-01 | 2024-10-18 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors EU101 - Solid Tumor, Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Eutilex | 110 | 2021-05-31 | 2024-03-15 |
| Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. Nivolumab - Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | Kidney Cancer Research Bureau | 26 | 2020-08-10 | 2023-03-08 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Belzutifan, Cabozantinib - Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 118 | 2018-09-27 | 2024-12-20 |
| A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC CT053PTSA - Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 10 | 2018-06-25 | 2021-03-24 |
| CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma CM082 combined with everolimus, CM082, Everolimus - Renal Cell Cancer Metastatic | Phase 3 | Unknown | AnewPharma | 390 | 2016-12-16 | 2021-02-08 |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) Sunitinib - Renal Cell Cancer Metastatic, Hypertension | Completed | Charite University, Berlin, Germany | 6 | 2015-11-01 | 2021-01-27 | |
| Interleukin-2 in Metastatic Kidney Cancer Interleukin-2 - Renal Cell Cancer Metastatic, Kidney Cancer Metastatic | Phase 2 | Terminated | Western Regional Medical Center | 7 | 2012-09-01 | 2018-02-08 |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer 5-Fluorouracil and Interferon - Gastrointestinal Cancer Metastatic, Renal Cell Cancer Metastatic | Phase 2 | Completed | Western Regional Medical Center | 18 | 2012-07-01 | 2018-03-21 |
Kidney Neoplasms (7) · Carcinoma, Renal Cell (6) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2) · Prostatic Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Hypertension (1) · Lymphoma, Large B-Cell, Diffuse (1) · Pleural Effusion, Malignant (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (11) · Neoplasms by Site (11) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Kidney Diseases (9) · Urologic Diseases (9) · Urologic Neoplasms (9) · Carcinoma (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Adenocarcinoma (6) · Disease Attributes (3)
3-(2,2,2-trimethylhydrazine)propionate (1) · Antibodies (1) · Biopsy (1) · Everolimus (1) · Fluorouracil (1) · Interferons (1) · Interleukin-2 (1) · Nivolumab (1) · Sunitinib (1) · belzutifan (1) · cabozantinib (1) · vorolanib (1)
Kidney Cancer Research Bureau (2) · Telix Pharmaceuticals (Innovations) Pty Limited (2) · Western Regional Medical Center (2) · AnewPharma (1) · Charite University, Berlin, Germany (1) · Eutilex (1) · Ourotech, Inc. (1) · PROspective Renal Cancer Cohort Foundation (1) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Spanish Oncology Genito-Urinary Group (1) · Sunshine Lake Pharma Co., Ltd. (1) · Zhe Chen (1) · Zumutor Biologics Inc. (1)
United States (6) · China (2) · Russia (2) · Albania (1) · Australia (1) · Azerbaijan (1) · Germany (1) · Japan (1) · Netherlands (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Walter Quan, MD (2) · Adriaan Bins, MD, PhD (1) · Ekaterini Boleti (1) · Guo Jun, PhD (1) · Hiroshi Onishi, MD, PhD (1) · Ilya Tsimafeyeu, M.D. (1) · Jun Guo, MD (1) · Jyotsna Fuloria (1) · Maloy Ghosh, PhD (1)
PMID 22980441, PMID 26706103, PMID 32335374, PMID 36459768, PMID 37011650, PMID 37434119, PMID 38172595, PMID 39756444, PMID 42414009
2025 (1)